• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Yosprala: A Fixed Dose Combination of Aspirin and Omeprazole
Cardiovascular disease is the leading cause of morbidity and mortality in the United States. Patients who survive a primary cerebrovascular or cardiovascular event are at increased risk of a subsequent occurrence. Antiplatelet therapy plays an essential role for secondary prevention in individuals with stroke, transient ischemic attack, acute or chronic artery disease, or peripheral arterial disease. Maintaining high-risk patients on low-dose aspirin therapy is a fundamental component of management. However, poor adherence, secondary to the drug’s gastrointestinal side effects, has been associated with negative cardiovas...
Source: Cardiology in Review - January 1, 2018 Category: Cardiology Tags: New Therapy Update Source Type: research

Emerging Roles of Protein Kinases in Microglia-mediated Neuroinflammation.
Abstract Neuroinflammation is mediated by resident central nervous system glia, neurons, peripherally derived immune cells, blood-brain barrier, and inflammatory mediators secreted from these cells. Neuroinflammation has been implicated in stroke and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis. Protein kinases have been one of the most exploited therapeutic targets in the current pharmacological research, especially in studies on cancer and inflammation. To date, 32 small-molecule protein kinase inhibitors have been approved by ...
Source: Biochemical Pharmacology - July 3, 2017 Category: Drugs & Pharmacology Authors: Lee SH, Suk K Tags: Biochem Pharmacol Source Type: research

Patent foramen ovale closure to prevent secondary neurologic events.
Abstract In October of 2016 the United States Food and Drug Administration approved the Amplatzer Patent Foramen Ovale (PFO) occluder device for use in patients with cryptogenic stroke, to reduce the risk of recurrent stroke. This event followed 15years of off-label use of atrial septal occluder devices, 3 randomized trials, and enormous controversy over the efficacy of this procedure. While none of the trials reached the primary endpoint needed to prove the efficacy of PFO closure in preventing recurrent stroke, meta-analyses and 5-year follow-up of 1 trial suggest that PFO closure decreases the risk of recurrent...
Source: European Journal of Internal Medicine - July 3, 2017 Category: Internal Medicine Authors: Jasper R, Blankenship JC Tags: Eur J Intern Med Source Type: research

Trans Fats On the Way Out? The FDA Moves to Ban Partially Hydrogenated Oils
(HealthCastle.com) You probably know that trans fats are bad for you: They raise your LDL (bad) cholesterol and can increase your risk of heart disease or stroke. Some countries have already banned them. In the United States, trans fats were not even required to be listed on product labels until 2006. Now, just seven years later, the U.S. Food and Drug Administration (FDA) is moving to phase artificial trans fats out from packaged foods sold in the United States.read more
Source: HealthCastle.com Nutrition Tips - written by Registered Dietitians - November 21, 2013 Category: Nutrition Source Type: news

Pages: 1  2  3  4  5  6  7